LEVI & KORSINSKY, LLP: APRIL 7, 2026 -- DEADLINE TO SEEK LEAD PLAINTIFF ROLE IN INOVIO PHARMACEUTICALS SECURITIES CLASS ACTION
18 mars, 14:00
LEVI & KORSINSKY, LLP: APRIL 7, 2026 -- DEADLINE TO SEEK LEAD PLAINTIFF ROLE IN INOVIO PHARMACEUTICALS SECURITIES CLASS ACTION
PR Newswire
NEW YORK, March 18, 2026
Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA
NEW YORK , March 18, 2026 /PRNewswire/ -- IMPORTANT DATE: April 7, 2026. Investors who wish to seek appointment as lead plaintiff in the Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities class action must file a motion by this date. Missing the deadline means forfeiting the opportunity to direct the litigation and select lead counsel.
Click here to participate in this action or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.
What is a Lead Plaintiff?
Under the Private Securities Litigation Reform Act of 1995 (PSLRA), the lead plaintiff is the member or members of the purported class who the Court determines is most capable of adequately representing the interests of class members. The lead plaintiff directs the litigation strategy and selects lead counsel for the class.
Lead Plaintiff Facts
- The lead plaintiff typically has the largest financial interest in the relief sought
- There is no cost to serve as lead plaintiff — attorneys work on contingency
- Lead plaintiffs select lead counsel and oversee case strategy
- Motions for lead plaintiff must be filed within 60 days of the first public announcement
- Institutional investors often serve as lead plaintiffs in major securities cases
Post-Deadline Procedures
After April 7, 2026, the Court will consider all lead plaintiff motions and appoint the lead plaintiff who it determines is most adequate. Those who do not seek lead plaintiff status but purchased INO securities during the Class Period remain class members and may recover if the case is successful.
Absent Class Member Rights
Class members who do not seek lead plaintiff status need not take any action at this time. If the case proceeds to settlement or judgment, absent class members will receive notice and opportunity to submit claims.
About the Inovio Class Action
The complaint alleges that Inovio and certain officers made materially false and misleading statements regarding medical device manufacturing and FDA regulatory pathway eligibility during the Class Period of October 10, 2023 through December 26, 2025.
"The lead plaintiff process is designed to ensure the class is represented by shareholders with substantial interests and the ability to adequately represent absent class members," explained Joseph E. Levi, Esq.
Get started on your claim or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.
Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com
SOURCE Levi & Korsinsky, LLP
Ämnen i artikeln
LEVI & KORSINSKY, LLP: APRIL 7, 2026 -- DEADLINE TO SEEK LEAD PLAINTIFF ROLE IN INOVIO PHARMACEUTICALS SECURITIES CLASS ACTION
18 mars, 14:00
LEVI & KORSINSKY, LLP: APRIL 7, 2026 -- DEADLINE TO SEEK LEAD PLAINTIFF ROLE IN INOVIO PHARMACEUTICALS SECURITIES CLASS ACTION
PR Newswire
NEW YORK, March 18, 2026
Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA
NEW YORK , March 18, 2026 /PRNewswire/ -- IMPORTANT DATE: April 7, 2026. Investors who wish to seek appointment as lead plaintiff in the Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities class action must file a motion by this date. Missing the deadline means forfeiting the opportunity to direct the litigation and select lead counsel.
Click here to participate in this action or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.
What is a Lead Plaintiff?
Under the Private Securities Litigation Reform Act of 1995 (PSLRA), the lead plaintiff is the member or members of the purported class who the Court determines is most capable of adequately representing the interests of class members. The lead plaintiff directs the litigation strategy and selects lead counsel for the class.
Lead Plaintiff Facts
- The lead plaintiff typically has the largest financial interest in the relief sought
- There is no cost to serve as lead plaintiff — attorneys work on contingency
- Lead plaintiffs select lead counsel and oversee case strategy
- Motions for lead plaintiff must be filed within 60 days of the first public announcement
- Institutional investors often serve as lead plaintiffs in major securities cases
Post-Deadline Procedures
After April 7, 2026, the Court will consider all lead plaintiff motions and appoint the lead plaintiff who it determines is most adequate. Those who do not seek lead plaintiff status but purchased INO securities during the Class Period remain class members and may recover if the case is successful.
Absent Class Member Rights
Class members who do not seek lead plaintiff status need not take any action at this time. If the case proceeds to settlement or judgment, absent class members will receive notice and opportunity to submit claims.
About the Inovio Class Action
The complaint alleges that Inovio and certain officers made materially false and misleading statements regarding medical device manufacturing and FDA regulatory pathway eligibility during the Class Period of October 10, 2023 through December 26, 2025.
"The lead plaintiff process is designed to ensure the class is represented by shareholders with substantial interests and the ability to adequately represent absent class members," explained Joseph E. Levi, Esq.
Get started on your claim or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.
Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com
SOURCE Levi & Korsinsky, LLP
Ämnen i artikeln
Analys
Svensk ekonomi
Aktierekommendationer
Bolidens ras
H&M
Analys
Svensk ekonomi
Aktierekommendationer
Bolidens ras
H&M
Marknadsöversikt
1 DAG %
Senast
1 mån
